Skip to content
EU
USA
EU
USA
Meet Relivion
Future Indications
Resources
Frequently Asked Questions
The Power of The Electric Brain
Device Fitting Overview
Important Safety Information
About Neurolief
In the News
Contact Us
Menu
Meet Relivion
Future Indications
Resources
Frequently Asked Questions
The Power of The Electric Brain
Device Fitting Overview
Important Safety Information
About Neurolief
In the News
Contact Us
IN THE
NEWS
Read the latest news about Neurolief and Relivion.
Neurolief’s Relivion® Secures Regulatory Approval in Japan, Pioneering At-Home Migraine Treatment
Neurolief Announces Strategic Equity Investment by Sawai Group Holdings
Neurolief Appoints Neurotechnology Business Leader Steve Beller as Chief Commercial Officer
Positive Results from the MOOD Trial Interim Analysis: Brain Neuromodulation Therapy for Major Depressive Disorder
New Data at AHS Demonstrate Substantial Results for Patients Using Neurolief's Digital Therapeutics Technology to Treat Migraine
Neurolief Appoints Experienced Finance Executive as Chief Financial Officer
Neurolief Launches a New U.S. Telehealth Channel Increasing Patient Access to the Relivion MG Migraine Therapy
Neurolief Appoints Neuromodulation Industry Leader Scott Drees as CEO
Neurolief Announces Publication of the RIME Pivotal Study for Relivion MG – a Digital Therapeutics Platform for Migraine
New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology
First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder
Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion®
Neurolief Announces Positive Results From RIME Clinical Study of Its Brain Neuromodulation System for Treating Acute Migraine
Relivion® Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine
Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion® in Greater China and South Korea
Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine
American Headache Society: Combined Occipital & Trigeminal Neurostimulation (Abstract)
Relivion Cleared in Europe – Granted based on data from RCT clinical trial
Neurolief Awarded Breakthrough Device Designation from FDA for Wearable Technology to Address Major Depression
Digital therapeutic device safe, effective in acute migraine
This Headset Could Treat Migraines
Neurolief gets CE-Mark for digital migraine treatment device
MedTech Strategist
European Headache Federation Conference: Brain Neuromodulation Digital Therapeutics
This Headset Could Treat Migraines
BrainTech Conference: Fighting the Opioids Crisis With Brain Neuromodulation Digital Therapeutics
NYC Neuromodulation Conference : Relivion Combined Stimulation Vs. Single Nerve Stim
NYC Neuromodulation Conference: Relivion for Rapid Pain Reduction in Occipital Migraine
ISRAEL 21C: Portable wearable device will offer over-the-counter alternative to pills or surgery to be used as needed
International Headache Society Conference 2017: Published Results of the Relivion OS-TNS Clinical Trial
Globes: Neurolief Develops Non-Invasive Migraine Treatment
ZWISCHENZEILEN: Israelis entwickeln Gerät zur Migränebehandlung (in German)
JNS: Israeli Breakthrough Device Developed to Aid Migraine Relief
Medical Device News Magazine: Neurolief’s Relivion™ Featured at Headache Symposium